FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP 1s : r tirzepatidecompound Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP 1s, which are not FDA approved and can pose risks to patients. FULL STORY:https: tinyurl.com 3ztf9uj2 Gray Market Peptides: So Much Hype, So Little Data Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link